STOCK TITAN

Hemogenyx Pharmaceuticals PLC Announces Conversion of Convertible Loan Notes

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Hemogenyx Pharmaceuticals has received a conversion notice from Mint Capital Advisors for £950,000 worth of Convertible Loan Notes, which will lead to the issuance of 24,547,803 new ordinary shares at a conversion price of £0.0387 each. These shares will be admitted to trading on the London Stock Exchange, expected on April 22, 2021. Following the issuance, the total number of ordinary shares in circulation will reach 494,343,020. The company has no immediate plans for further drawdowns from the Convertible Notes Facility.

Positive
  • Issuance of 24,547,803 new ordinary shares will strengthen capital structure.
  • No immediate plans for further drawdowns, indicating prudent financial management.
Negative
  • Conversion of loan notes may dilute existing shareholders' equity.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK / ACCESSWIRE / April 16, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £950,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021.

Pursuant to the conversion, the Company will issue, in aggregate, 24,547,803 new ordinary shares of £0.01 each in the capital of the Company (the "New Ordinary Shares") at a conversion price of £0.0387 per Ordinary Share.

Application will be made to the Financial Conduct Authority and to the London Stock Exchange for the admission of the New Ordinary Shares to the standard segment of the Official List and to trading on the London Stock Exchange's main market for listed securities, respectively ("Admission"). It is expected that Admission will occur at 8.00 a.m. on or around 22 April 2021. The New Ordinary Shares will rank pari passu with the existing issued Ordinary Shares in the Company.

The Company does not have any immediate plans for further drawdowns from the Convertible Notes Facility.

Total Voting Rights

Following Admission of the New Ordinary Shares, the Company will have 494,343,020 Ordinary Shares of £0.01 each in issue with voting rights. The Company does not hold any shares in treasury. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Unless defined herein, or the context requires otherwise, capitalised terms used in this announcement carry the same meaning as those ascribed to them in the Company's announcement of 18 November 2020.

The person responsible for arranging for the release of this announcement on behalf of the Company is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC



View source version on accesswire.com:
https://www.accesswire.com/640723/Hemogenyx-Pharmaceuticals-PLC-Announces-Conversion-of-Convertible-Loan-Notes

FAQ

What is the significance of the Convertible Loan Notes conversion by Hemogenyx?

The conversion allows Hemogenyx to issue new shares, strengthening its capital base but may dilute existing shareholders' equity.

When will the new ordinary shares of Hemogenyx be admitted for trading?

The new ordinary shares are expected to be admitted for trading on April 22, 2021.

How many total ordinary shares will be outstanding after the conversion?

After the conversion, there will be a total of 494,343,020 ordinary shares outstanding.

What is the conversion price per share for the Convertible Loan Notes?

The conversion price is set at £0.0387 per ordinary share.

Does Hemogenyx plan further drawdowns from the Convertible Notes Facility?

Hemogenyx does not have any immediate plans for further drawdowns from the Convertible Notes Facility.

HEMOGENYX PHARMACEUTICALS

OTC:HOPHF

HOPHF Rankings

HOPHF Latest News

HOPHF Stock Data

20.73M
1.21B
10.73%
0.83%
Biotechnology
Healthcare
Link
United States of America
London